Form 4: Neurocrine Biosciences Director Acquires Stock Options and Restricted Stock Units

Director Johanna Mercier reports acquisition of stock options and restricted stock units in Neurocrine Biosciences.

Summary

• On May 22, 2024, Johanna Mercier, a director of Neurocrine Biosciences Inc. (NBIX), acquired restricted stock units (RSUs) and non-qualified stock options.
• Mercier acquired 1,435 restricted stock units, each representing the right to receive one share of Neurocrine Biosciences' common stock upon vesting.
• These RSUs will vest in full on May 22, 2025.
• Mercier also acquired 2,982 non-qualified stock options with an exercise price of $139.43.
• The options vest in 12 monthly installments beginning June 22, 2024, and expire on May 22, 2034.
• Following these transactions, Mercier directly owns 1,435 shares underlying the RSUs and 2,982 shares underlying the stock options.

Sentiment

Score: 6

Explanation: The sentiment is neutral as it reports a standard transaction. The acquisition of stock options and RSUs by a director is generally viewed as a positive sign, but it's a routine event.

Positives

• The acquisition of stock options and RSUs by a director signals confidence in the company's future performance.

Future Outlook

The vesting schedules for the RSUs and stock options indicate a long-term incentive structure for the director.

Industry Context

Stock option and RSU grants are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders.

Comparison to Industry Standards

• Comparing the vesting schedule and exercise price to similar grants at companies like Amgen (AMGN) or Biogen (BIIB) could provide context on the competitiveness of Neurocrine's compensation packages.
• Industry benchmarks for executive compensation often consider company size, performance, and the executive's role.

Stakeholder Impact

• The acquisition of stock options and RSUs aligns the director's interests with those of shareholders, potentially incentivizing actions that increase shareholder value.

Key Dates